| ORANY |
ORANY |
72%
|
rting, reporting of certain deviations and adverse experiences, providing the regulatory authorities with updated safety and efficacy information, drug sampling and distribution requirements, and com… |
| ORANY |
ORANY |
72%
|
Reciprocal relationship from ORANY graph: Reciprocal relationship from BLTE graph: rting, reporting of certain deviations and adverse experiences, providing the regulatory authorities with updated sa… |
| BELITE-BIO-HOLDINGS-CORP |
BELITE-BIO-HOLDINGS-CORP |
62%
|
n and our results of operations. In the event of the successful development and commercialization of one or more of our product candidates, we expect to fund our operations in part with revenue gener… |
| BELITE-BIO-LLC |
BELITE-BIO-LLC |
62%
|
n and our results of operations. In the event of the successful development and commercialization of one or more of our product candidates, we expect to fund our operations in part with revenue gener… |
| CATALYST-PHARMS-INC |
CATALYST-PHARMS-INC |
62%
|
e highest industry standards to select the CROs that are going to conduct the services in order to meet FDA and other regulatory requirements. Manufacturing and Supply We currently rely on high-quali… |
| COMPANY-BELITE-BIO-INC |
COMPANY-BELITE-BIO-INC |
62%
|
s, including, but not limited to: ● announcements of regulatory approval or a complete response letter, or specific label indications or patient populations for a drug’s use, or changes or delays in … |
| COMPANY-LIN-BIOSCIENCE-INTERNATIONAL-LTD |
COMPANY-LIN-BIOSCIENCE-INTERNATIONAL-LTD |
62%
|
e of these events could be the basis for FDA action, including injunction, request for recall, seizure, or total or partial suspension of production. Certain of our clinical supplies may be manufactu… |
| DB |
Deutsche Bank Aktiengesellschaft |
62%
|
Reciprocal relationship from DB graph: Reciprocal relationship from BLTE graph: to ADS holders and the depositary services fee are charged by the depositary bank to the holders of record of ADSs as o… |
| HK-LIMITED |
HK-LIMITED |
62%
|
n and our results of operations. In the event of the successful development and commercialization of one or more of our product candidates, we expect to fund our operations in part with revenue gener… |
| JAPAN-BELITE-BIO-JAPAN-INC |
JAPAN-BELITE-BIO-JAPAN-INC |
62%
|
n and our results of operations. In the event of the successful development and commercialization of one or more of our product candidates, we expect to fund our operations in part with revenue gener… |
| LIN-BIOSCIENCE-CO-LTD |
LIN-BIOSCIENCE-CO-LTD |
62%
|
s mainly engaged in research and development of tinlarebant (a/k/a LBS-008) and LBS-009. In March 2018, as a part of a reorganization, Lin BioScience, Inc. established the Company (formerly known as … |
| LIN-BIOSCIENCE-INC |
LIN-BIOSCIENCE-INC |
62%
|
e highest industry standards to select the CROs that are going to conduct the services in order to meet FDA and other regulatory requirements. Manufacturing and Supply We currently rely on high-quali… |
| LIN-BIOSCIENCE-INTERNATIONAL-LTD |
LIN-BIOSCIENCE-INTERNATIONAL-LTD |
62%
|
e highest industry standards to select the CROs that are going to conduct the services in order to meet FDA and other regulatory requirements. Manufacturing and Supply We currently rely on high-quali… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
s, including, but not limited to: ● announcements of regulatory approval or a complete response letter, or specific label indications or patient populations for a drug’s use, or changes or delays in … |
| RBP4-PTY-LTD |
RBP4-PTY-LTD |
62%
|
n and our results of operations. In the event of the successful development and commercialization of one or more of our product candidates, we expect to fund our operations in part with revenue gener… |
| SEE-NOVARTIS-PHARM-CORP |
SEE-NOVARTIS-PHARM-CORP |
62%
|
rting, reporting of certain deviations and adverse experiences, providing the regulatory authorities with updated safety and efficacy information, drug sampling and distribution requirements, and com… |
| SHANGHAI-LIMITED |
SHANGHAI-LIMITED |
62%
|
n and our results of operations. In the event of the successful development and commercialization of one or more of our product candidates, we expect to fund our operations in part with revenue gener… |
| SWISS-AG |
SWISS-AG |
62%
|
n and our results of operations. In the event of the successful development and commercialization of one or more of our product candidates, we expect to fund our operations in part with revenue gener… |
| US-DEUTSCHE-BANK-TRUST-COMPANY |
US-DEUTSCHE-BANK-TRUST-COMPANY |
62%
|
to ADS holders and the depositary services fee are charged by the depositary bank to the holders of record of ADSs as of the applicable ADS record date. The depositary fees payable for cash distribut… |
